|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date10 Jan 2022 |
[14C]阿可拉定在中国成年男性健康志愿者体内的物质平衡与生物转化I期临床试验
[Translation] Phase I clinical trial of [14C] acoradine in Chinese adult male healthy volunteers for mass balance and biotransformation
本试验旨在评价中国男性健康志愿者单剂量口服[14C]阿可拉定后的物质平衡、代谢转化途径及药代动力学。揭示阿可拉定在人体内的药代动力学整体特征,为药物的合理使用提供参考。
[Translation] The aim of this study was to evaluate the mass balance, metabolic pathways and pharmacokinetics of single-dose oral [14C]acoradine in Chinese male healthy volunteers. To reveal the overall characteristics of the pharmacokinetics of acridine in the human body, and to provide a reference for the rational use of the drug.
Comparison of Efficacy and Safety of Icaritin Versus Sorafenib in First-line Treatment of PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects: a Multicenter, Randomized, Opened Phase III Clinical Trial
The primary efficacy index of this study is to compare the OS of the two groups.
Comparison of Efficacy and Safety of Icaritin Versus Cinobufotalin in First-line Treatment of Advanced Hepatocellular Carcinoma Subjects: a Multicenter, Randomized, Double-blind, Double-dummy Phase III Clinical Trial
The enriched HBV-related advanced HCC patient population (composite biomarker score ≥ 2) and overall survival (OS) were compared between the two groups.
100 Clinical Results associated with Beijing Shenogen Biomedical Co., Ltd
0 Patents (Medical) associated with Beijing Shenogen Biomedical Co., Ltd
100 Deals associated with Beijing Shenogen Biomedical Co., Ltd
100 Translational Medicine associated with Beijing Shenogen Biomedical Co., Ltd